表紙
市場調査レポート

尿路感染症:パイプライン製品の分析

Urinary Tract Infections - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 232831
出版日 ページ情報 英文 139 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
尿路感染症:パイプライン製品の分析 Urinary Tract Infections - Pipeline Review, H2 2015
出版日: 2015年09月30日 ページ情報: 英文 139 Pages
概要

尿路感染症(UTI)は、細菌によって引き起こされる尿路の感染症です。女性は、発症する危険性が男性より高くなっています。強い持続的な尿意、排尿時の灼熱感、混濁尿、骨盤痛(女性)、直腸痛(男性)などの症状が見られます。治療には、抗生物質を使用します。

当レポートでは、尿路感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

尿路感染症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Achaogen Inc.
  • Adenium Biotech ApS
  • AstraZeneca PLC
  • ConjuGon, Inc.
  • Cubist Pharmaceuticals, Inc.
  • Da Volterra
  • DexTech Medical AB
  • FOB Synthesis, Inc.
  • GlycoVaxyn AG
  • Melinta Therapeutics, Inc
  • Merck & Co., Inc.
  • MerLion Pharmaceuticals Pte Ltd
  • Nabriva Therapeutics AG
  • NovaBay Pharmaceuticals, Inc.
  • Nymox Pharmaceutical Corporation
  • Osel Inc.
  • Paratek Pharmaceuticals, Inc.
  • Sequoia Sciences, Inc.
  • 塩野義製薬
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.
  • The Medicines Company
  • Urinary Tract Infections

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (ceftaroline fosamil + avibactam sodium)
  • (ceftazidime + avibactam sodium)
  • (ceftolozane sulfate + tazobactam sodium)
  • (meropenem+ RPX-7009)
  • AA-139
  • auriclosene
  • C-1205
  • CatDex
  • cefepime
  • DAV-210
  • delafloxacin
  • Drugs to Inhibit COX-2 for Urinary Tract Infections
  • EBX-002
  • eravacycline
  • Escherichia coli vaccine
  • extraintestinal pathogenic escherichia coli vaccine
  • finafloxacin
  • FSI-1686
  • GP-4
  • klebsiella pneumoniae vaccine
  • LACTIN-V
  • Micselon
  • Nu-2
  • Nu-3
  • NXB-4221
  • omadacycline
  • plazomicin sulfate
  • Proteins for Infectious Deseases
  • relebactam
  • S-649266
  • Small Molecules to Inhibit 23S Ribosomal RNA for Infections
  • Vaccine for Urinary Tract Infection
  • ZTI-01 1

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6971IDB

Summary

Global Markets Direct's, 'Urinary Tract Infections - Pipeline Review, H2 2015', provides an overview of the Urinary Tract Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Urinary Tract Infections Overview
  • Therapeutics Development
    • Pipeline Products for Urinary Tract Infections - Overview
    • Pipeline Products for Urinary Tract Infections - Comparative Analysis
  • Urinary Tract Infections - Therapeutics under Development by Companies
  • Urinary Tract Infections - Therapeutics under Investigation by Universities/Institutes
  • Urinary Tract Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Urinary Tract Infections - Products under Development by Companies
  • Urinary Tract Infections - Products under Investigation by Universities/Institutes
  • Urinary Tract Infections - Companies Involved in Therapeutics Development
    • Achaogen Inc.
    • Adenium Biotech ApS
    • AstraZeneca Plc
    • ConjuGon, Inc.
    • Da Volterra
    • DexTech Medical AB
    • Enteris BioPharma, Inc.
    • GlaxoSmithKline Plc
    • Melinta Therapeutics, Inc
    • Merck & Co., Inc.
    • MerLion Pharmaceuticals Pte Ltd
    • Nabriva Therapeutics AG
    • Nippon Shinyaku Co., Ltd.
    • NovaBay Pharmaceuticals, Inc.
    • Nymox Pharmaceutical Corporation
    • Paratek Pharmaceuticals, Inc.
    • Pivot Pharmaceuticals Inc
    • Sequoia Sciences, Inc.
    • Shionogi & Co., Ltd.
    • Syntiron LLC
    • The Medicines Company
    • Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Urinary Tract Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ceftazidime + avibactam sodium) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (ceftolozane sulfate + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (meropenem+ RPX-7009) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AA-139 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • auriclosene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-7634 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-9074 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-9529 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-9563 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-1205 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CatDex - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cefepime - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DAV-210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit COX-2 for Urinary Tract Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EBX-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Escherichia coli vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • finafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fosfomycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GP-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-63871860 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Klebsiella pneumoniae vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Micselon - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nu-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NXB-4221 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Proteins for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • prulifloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • relebactam - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-649266 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tobramycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • urinary tract infection vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZS-06 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Urinary Tract Infections - Recent Pipeline Updates
  • Urinary Tract Infections - Dormant Projects
  • Urinary Tract Infections - Discontinued Products
  • Urinary Tract Infections - Product Development Milestones
    • Featured News & Press Releases
      • Sep 17, 2015: Paratek's Omadacycline, Demonstrates Broad Spectrum Activity in Pathogens Relevant in Skin Infections, Community-Acquired Pneumonia and Urinary Tract Infections
      • Sep 02, 2015: Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
      • Aug 03, 2015: Paratek Pharmaceuticals to Present Data at ICAAC 2015
      • Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections
      • Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections
      • Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
      • Apr 27, 2015: Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
      • Apr 23, 2015: Actavis Launches AVYCAZ (Ceftazidime-Avibactam) Anti-Infective In U.S.
      • Apr 09, 2015: Achaogen to Present at 14th Annual Needham Healthcare Conference
      • Feb 25, 2015: Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Urinary Tract Infections, H2 2015
  • Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Urinary Tract Infections - Pipeline by Achaogen Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Adenium Biotech ApS, H2 2015
  • Urinary Tract Infections - Pipeline by AstraZeneca Plc, H2 2015
  • Urinary Tract Infections - Pipeline by ConjuGon, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Da Volterra, H2 2015
  • Urinary Tract Infections - Pipeline by DexTech Medical AB, H2 2015
  • Urinary Tract Infections - Pipeline by Enteris BioPharma, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Urinary Tract Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015
  • Urinary Tract Infections - Pipeline by Merck & Co., Inc., H2 2015
  • Urinary Tract Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2015
  • Urinary Tract Infections - Pipeline by Nabriva Therapeutics AG, H2 2015
  • Urinary Tract Infections - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
  • Urinary Tract Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Nymox Pharmaceutical Corporation, H2 2015
  • Urinary Tract Infections - Pipeline by Paratek Pharmaceuticals, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Pivot Pharmaceuticals Inc, H2 2015
  • Urinary Tract Infections - Pipeline by Sequoia Sciences, Inc., H2 2015
  • Urinary Tract Infections - Pipeline by Shionogi & Co., Ltd., H2 2015
  • Urinary Tract Infections - Pipeline by Syntiron LLC, H2 2015
  • Urinary Tract Infections - Pipeline by The Medicines Company, H2 2015
  • Urinary Tract Infections - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Urinary Tract Infections Therapeutics - Recent Pipeline Updates, H2 2015
  • Urinary Tract Infections - Dormant Projects, H2 2015
  • Urinary Tract Infections - Dormant Projects (Contd..1), H2 2015
  • Urinary Tract Infections - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Urinary Tract Infections, H2 2015
  • Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top